CN100363061C - 包含活性银的抗微生物隐形眼镜及其生产方法 - Google Patents
包含活性银的抗微生物隐形眼镜及其生产方法 Download PDFInfo
- Publication number
- CN100363061C CN100363061C CNB01822766XA CN01822766A CN100363061C CN 100363061 C CN100363061 C CN 100363061C CN B01822766X A CNB01822766X A CN B01822766XA CN 01822766 A CN01822766 A CN 01822766A CN 100363061 C CN100363061 C CN 100363061C
- Authority
- CN
- China
- Prior art keywords
- eyeglass
- silver
- weight
- activation
- lens
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 33
- 230000000845 anti-microbial effect Effects 0.000 title claims abstract description 22
- 238000004519 manufacturing process Methods 0.000 title abstract description 11
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 47
- 229910052709 silver Inorganic materials 0.000 claims description 47
- 239000004332 silver Substances 0.000 claims description 47
- 239000000203 mixture Substances 0.000 claims description 29
- 239000007800 oxidant agent Substances 0.000 claims description 26
- 230000004913 activation Effects 0.000 claims description 25
- 238000006243 chemical reaction Methods 0.000 claims description 20
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 claims description 20
- 239000005708 Sodium hypochlorite Substances 0.000 claims description 17
- 230000001590 oxidative effect Effects 0.000 claims description 16
- 230000003287 optical effect Effects 0.000 claims description 14
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical group OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 13
- 230000001464 adherent effect Effects 0.000 claims description 12
- 239000000017 hydrogel Substances 0.000 claims description 10
- 229920000642 polymer Polymers 0.000 claims description 9
- 239000011521 glass Substances 0.000 claims description 7
- 229920001296 polysiloxane Polymers 0.000 claims description 7
- 239000000178 monomer Substances 0.000 claims description 6
- NLAIHECABDOZBR-UHFFFAOYSA-M sodium 2,2-bis(2-methylprop-2-enoyloxymethyl)butyl 2-methylprop-2-enoate 2-hydroxyethyl 2-methylprop-2-enoate 2-methylprop-2-enoate Chemical compound [Na+].CC(=C)C([O-])=O.CC(=C)C(=O)OCCO.CCC(COC(=O)C(C)=C)(COC(=O)C(C)=C)COC(=O)C(C)=C NLAIHECABDOZBR-UHFFFAOYSA-M 0.000 claims description 5
- 230000000813 microbial effect Effects 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 239000000460 chlorine Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 claims description 3
- AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 150000004965 peroxy acids Chemical class 0.000 claims description 3
- 239000012286 potassium permanganate Substances 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- 229920001616 Polymacon Polymers 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 22
- 244000005700 microbiome Species 0.000 description 20
- 239000000243 solution Substances 0.000 description 18
- 102100026735 Coagulation factor VIII Human genes 0.000 description 13
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 13
- 230000001580 bacterial effect Effects 0.000 description 13
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 11
- 229910052739 hydrogen Inorganic materials 0.000 description 11
- -1 fluoro acrylic ester Chemical class 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 239000003999 initiator Substances 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 229960002163 hydrogen peroxide Drugs 0.000 description 5
- HWSSEYVMGDIFMH-UHFFFAOYSA-N 2-[2-[2-(2-methylprop-2-enoyloxy)ethoxy]ethoxy]ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCOCCOCCOC(=O)C(C)=C HWSSEYVMGDIFMH-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Chemical compound CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- QCEYBMNLGBUVTQ-UHFFFAOYSA-N N-methyl-N-methylsilylmethanamine Chemical compound C[SiH2]N(C)C QCEYBMNLGBUVTQ-UHFFFAOYSA-N 0.000 description 3
- 229910019093 NaOCl Inorganic materials 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000005022 packaging material Substances 0.000 description 3
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 3
- 239000004926 polymethyl methacrylate Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 2
- UURVHRGPGCBHIC-UHFFFAOYSA-N 3-(ethenoxycarbonylamino)propanoic acid 4-[[[[[[[[[[[[[[[[[[[[[[[[[[[4-ethenoxycarbonyloxybutyl(dimethyl)silyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]butyl ethenyl carbonate 1-ethenylpyrrolidin-2-one ethenyl N-[3-tris(trimethylsilyloxy)silylpropyl]carbamate Chemical compound C=CN1CCCC1=O.OC(=O)CCNC(=O)OC=C.C[Si](C)(C)O[Si](CCCNC(=O)OC=C)(O[Si](C)(C)C)O[Si](C)(C)C.C[Si](C)(CCCCOC(=O)OC=C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)CCCCOC(=O)OC=C UURVHRGPGCBHIC-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 101710134784 Agnoprotein Proteins 0.000 description 2
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 229910010293 ceramic material Inorganic materials 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- BLFZMXOCPASACY-UHFFFAOYSA-N 1,4-bis(propan-2-ylamino)anthracene-9,10-dione Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C(NC(C)C)=CC=C2NC(C)C BLFZMXOCPASACY-UHFFFAOYSA-N 0.000 description 1
- 239000012956 1-hydroxycyclohexylphenyl-ketone Substances 0.000 description 1
- ALDLWNVQGSGVDF-UHFFFAOYSA-N 2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethanol;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CC(=C)C(O)=O.OCCOCCOCCOCCO ALDLWNVQGSGVDF-UHFFFAOYSA-N 0.000 description 1
- RIWRBSMFKVOJMN-UHFFFAOYSA-N 2-methyl-1-phenylpropan-2-ol Chemical compound CC(C)(O)CC1=CC=CC=C1 RIWRBSMFKVOJMN-UHFFFAOYSA-N 0.000 description 1
- ZSPOJBDHHFFJAP-UHFFFAOYSA-M 3-chlorobenzoate;tetrabutylazanium Chemical compound [O-]C(=O)C1=CC=CC(Cl)=C1.CCCC[N+](CCCC)(CCCC)CCCC ZSPOJBDHHFFJAP-UHFFFAOYSA-M 0.000 description 1
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 1
- CUCUKLJLRRAKFN-UHFFFAOYSA-N 7-Hydroxy-(S)-usnate Chemical compound CC12C(=O)C(C(=O)C)C(=O)C=C1OC1=C2C(O)=C(C)C(O)=C1C(C)=O CUCUKLJLRRAKFN-UHFFFAOYSA-N 0.000 description 1
- 241000224422 Acanthamoeba Species 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- UKLDJPRMSDWDSL-UHFFFAOYSA-L [dibutyl(dodecanoyloxy)stannyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[Sn](CCCC)(CCCC)OC(=O)CCCCCCCCCCC UKLDJPRMSDWDSL-UHFFFAOYSA-L 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000010065 bacterial adhesion Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- MQDJYUACMFCOFT-UHFFFAOYSA-N bis[2-(1-hydroxycyclohexyl)phenyl]methanone Chemical compound C=1C=CC=C(C(=O)C=2C(=CC=CC=2)C2(O)CCCCC2)C=1C1(O)CCCCC1 MQDJYUACMFCOFT-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 208000024754 bloodshot eye Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000003575 carbonaceous material Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 229920001427 mPEG Polymers 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- UJMWVICAENGCRF-UHFFFAOYSA-N oxygen difluoride Chemical compound FOF UJMWVICAENGCRF-UHFFFAOYSA-N 0.000 description 1
- 201000005675 papillary conjunctivitis Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920001197 polyacetylene Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 1
- 229920006352 transparent thermoplastic Polymers 0.000 description 1
- IXSPLXSQNNZJJU-UHFFFAOYSA-N trimethyl(silyloxy)silane Chemical compound C[Si](C)(C)O[SiH3] IXSPLXSQNNZJJU-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G02—OPTICS
- G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
- G02C7/00—Optical parts
- G02C7/02—Lenses; Lens systems ; Methods of designing lenses
- G02C7/04—Contact lenses for the eyes
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B1/00—Optical elements characterised by the material of which they are made; Optical coatings for optical elements
- G02B1/04—Optical elements characterised by the material of which they are made; Optical coatings for optical elements made of organic materials, e.g. plastics
- G02B1/041—Lenses
- G02B1/043—Contact lenses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
- A61L12/088—Heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L2300/104—Silver, e.g. silver sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
Landscapes
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Optics & Photonics (AREA)
- General Physics & Mathematics (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
- Eyeglasses (AREA)
- Treatments Of Macromolecular Shaped Articles (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
本发明公开一种包含>约0.01重量%活化银的光学透明的抗微生物镜片,以及镜片的生产、使用、和保存方法。
Description
有关的申请
本申请要求专利保护2000年12月21日提交的临时专利申请USNo.60/257,317的优先权。
发明领域
本发明涉及具有抗微生物性能的光学透明镜片以及它们的生产、使用和保存方法。
发明背景
从十九世纪五十年代起,在商业上一直使用隐形眼镜来改善视力。第一个隐形眼镜是由硬质材料制成的。虽然目前还采用这些镜片,但由于它们起初的舒适性较差和它们的氧渗透率较低,所以它们并不适合所有的患者。该领域后来的发展,产生了基于水凝胶的软性隐形眼镜,今天它们是极其流行的。许多用户都觉得软性镜片比较舒服,提高的舒适程度,使软性隐形眼镜用户戴镜的时数,远远多于硬质隐形眼镜的用户。
尽管这是个优点,但延长镜片的使用时数可能促进细菌和其它微生物,特别是绿脓假单胞菌在软性隐形眼镜表面上的集聚,对戴软性隐形眼镜者而言,细菌或其它微生物的集聚并不是仅有的,在使用硬质隐形眼镜的过程中也可能发生。
因此,需要生产能抑制细菌或其它微生物在隐形眼镜表面上生长和/或附着的隐形眼镜。还需要生产不促进细菌或其它微生物在隐形眼镜表面上附着和/或生长的隐形眼镜。还需要生产能抑制与细菌或其它微生物生长有关的不利反应的隐形眼镜。
人们已经公认需要生产能抑制细菌生长的隐形眼镜。在US-5,213,801中公开了抗微生物隐形眼镜的生产,其中将软性隐形眼镜内的抗微生物金属陶瓷材料包含在接触镜片中。这种方法包括许多步骤,可能并不适合在生产环境中生产所有类型的镜片。这些步骤包括,制备细到足以在隐形眼镜中使用的银的陶瓷材料,然后制造含有粉末状陶瓷的镜片。然而,包含这些类型材料的镜片,往往使隐形眼镜用户所需的透明度不够。
虽然已经知道这些方法和镜片,但仍需要能抑制细菌或其它微生物生长和/或附着,以及光学透明度足够的其它隐形眼镜,和生产这些镜片的方法。本发明寻求满足的,正是这种需求。
发明详述
本发明包括具有抗微生物性能的光学透明镜片,其中包括>约0.01重量%的活性银,该镜片基本上由,或由>约0.01重量%的活性银组成。这里所用的短语“光学透明的”,系指光学透明度可与目前市售的镜片例如etafilcon A和balafilcon A等相比的镜片。术语“镜片”,系指保留在眼内或眼上的opthalmic装置。这些装置可以提供光学矫正,也可以是装饰品。术语镜片包括但不限于软性接触镜片、硬质接触镜片、眼内镜片(intraocularlenses)、覆盖镜片(overlay lenses)、用于眼睛的插件(ocular inserts)、和矫正视力的插件(optical inserts)。典型的硬质接触镜片是由聚合物制造的,这些聚合物包括但不限于聚甲基丙烯酸甲酯、聚硅氧烷丙烯酸酯、氟代丙烯酸酯、氟代醚、聚乙炔、和聚酰亚胺的聚合物,其中代表性实例的制备方法,可以在JP200010055、JP6123860、和US-4,330,383中找到。典型的软性接触镜片是由聚硅氧烷弹性体或水凝胶制造的,例如但不限于由聚硅氧烷水凝胶和氟代水凝胶制造。代表性软性接触镜片的制备,可以在US-5,710,302、WO9421698、EP406161、JP2000016905、US-5,998,498、US Pat.App.09/532,943、2000年8月30日提交的US Pat.App.09/532,943的后续部分、和US-6,087,415中找到。市售的软性隐形眼镜的实例,包括但不限于etafilconA、genfilcon A、lenefilcon A、polymacon、和lotrafilcon A。优选的接触镜片是在US-5,998,498、US Pat.App.09/532,943、2000年8月30日提交的US Pat.App.09/532,943的后续部分、US-6,087,415中制备的etafilcon A、balafilcon A、和聚硅氧烷水凝胶。本发明的眼内镜片可以采用已知的材料制造。例如这些镜片可以由刚性的材料制造,其中包括但不限于聚甲基丙烯酸甲酯、聚苯乙烯、和聚碳酸酯等,以及它们的组合。此外,可以使用的挠性材料,包括但不限于水凝胶、聚硅氧烷材料、丙烯酸类材料、和碳氟化合物材料等,或它们的组合。在WO0026698、WO0022460、WO9929750、WO9927978、WO0022459、和JP2000107277中叙述了典型的眼内镜片。本发明所有上述的镜片,都可以采用用于涂覆镜片的许多试剂涂覆。例如可以采用US-6,087,415的步骤、组合物、和方法,特此引入该专利作为对这些步骤、组合物、和方法的参考。特此全文引入在本申请中提到的所有文献作为参考。
术语“活化的银”,系指在制造镜片之前已经加到镜片聚合物中,随后用氧化剂处理活化的银。氧化剂包括但不限于过氧化氢、次氯酸钠、过氧酸、溴、氯、铬酸、高锰酸钾、和碘。优选的氧化剂是次氯酸钠。可将氧化剂分散或溶解在水溶液例如无离子水中,制成的镜片可用该溶液洗涤或浸泡一段时间。氧化剂在水溶液中的浓度为约0.1至约50重量%,该百分率是基于溶液的重量%(或体积)计算的,优选约0.4至约30重量%,更优选约0.6至约15重量%。用氧化剂处理镜片的这段时间为约10s至约10h,优选约1至约10min。
被氧化的银包括但不限于粒度为-30、-60、或-325目,或平均粒度为2-8μm的粉末状银;纳米尺寸的粉末;和由聚合物骨架中离子银还原生成的银。镜片中的银量>0.01重量%,该百分率是基于未水合的单体成分的重量计算的。银的重量百分率为约0.01至约0.3重量%,更优选约0.02至约0.2重量%,最优选约0.03至约0.1重量%。
术语“抗微生物性能”,系指具有一种或多种下列性能的镜片,能抑制细菌或其它微生物对镜片的附着,能抑制细菌或其它微生物在镜片上的生长,和能杀灭镜片表面上或从镜片延伸的半径内的细菌或其它微生物(此后将细菌或其它微生物对镜片的附着、细菌或其它微生物在镜片上的生长、和细菌或其它微生物在镜片表面上的存在,统称为“微生物的产生”)。特别优选本发明的镜片在玻璃试管实验中具有至少1-活细菌或其它微生物减少率(抑制率≥90%)的对数(log),最特别优选具有约2-活细菌或其它微生物减少率(抑制率≥99%)的对数。这些细菌或其它微生物,包括但不限于一些在眼中找到的微生物,特别是绿脓假单胞菌、棘阿米巴属细菌(Acanthanmoeba)、金黄色葡萄球菌、大肠杆菌、表皮葡萄球菌(Staphyloccusepidermidus)、和粘质沙雷氏菌。
本发明还包括减少戴镜者对不利微生物反应的方法,其中包括提供具有抗微生物性能的光学透明镜片的步骤,该方法基本上由,或由提供具有抗微生物性能的光学透明镜片的步骤组成,这些镜片包括>约0.01重量%的活化银,它们基本上由,或由>约0.01重量%的活化银组成。术语镜片、活化银、光学透明的、和抗微生物性能,全都具有它们上述的含义和优选的范围。优选的戴镜者是人。短语“与微生物感染有关的不利情况”,包括但不限于下列情况:溃疡性(微生物,传染性)角膜炎、浸润性角膜炎、无症状的浸润物、接触镜片诱发的周边溃疡、接触镜片诱发的急性红眼、和接触镜片诱发的乳头状结膜炎。虽然在戴镜者眼中细菌或其它微生物种群的任何减少,都可以减轻与微生物感染有关的不利影响,但优选本发明的镜片在标准的玻璃试管实验中,能抑制细菌和其它微生物的生长达约50%至约100%,更优选约80%至约100%,最优选约90%至约100%。特别优选本发明的镜片具有1-活细菌或其它微生物减少率(抑制率≥90%)的对数,最特别优选具有1-活细菌或其它微生物减少率(抑制率≥99%)的对数。
本发明还包括生产具有抗微生物性能的光学透明镜片的方法,该镜片包括>约0.01重量%的活化银,它们基本上由,或由>约0.01重量%的活化银组成,该方法包括用氧化剂处理含银的镜片,该方法基本上由,或由用氧化剂处理含银的镜片组成。术语镜片、活化银、光学透明的、和抗微生物性能,都具有它们上述的含义和优选的范围。术语“氧化剂”包括但不限于过氧化氢、次氯酸钠、过氧酸、溴、氯、铬酸、高锰酸钾、和碘,其中优选的氧化剂是次氯酸钠。虽然可以以许多方式将氧化剂施加到镜片上,但优选将氧化剂分散或溶解在水溶液例如无离子水中,制成的镜片可以用该溶液洗涤或浸泡一段时间。氧化剂在水溶液中的浓度为约0.1至约50重量%,优选约0.4至约30重量%,更优选约0.6至约15重量%,该百分率是基于溶液的重量%计算的。用氧化剂处理镜片的这段时间,为约10s至约10h,优选约1-10min。
本发明还包括具有抗微生物性能的镜片盒,其中包括>约0.01重量%的活化银,该镜片盒基本上由,或由>约0.01重量%的活化银组成。术语镜片、活化银、光学透明的、和抗微生物性能,全都具有它们上述的含义和优选的范围。术语镜片盒系指为了限定空间而采用的容器,在该空间中保存不在使用的镜片。该术语包括镜片的包装材料,包装材料包括任意个单元,镜片固化后就储存在这些单元中。这种包装材料的实例包括但不限于单个使用的泡罩型包装等。
在U.S.P.5,515,117的图3中示出一种这样的容器,特此全文引入作为参考。可以将银包含在镜片容器22,盖24,或镜片篮26中,其中优选将它们包含在镜片容器或镜片篮中(这些数字系指US-5,515,117中的数字)。在这种镜片盒中的银,可以采用对本发明的镜片所述的相同方法活化。
除了活化银以外,该容器的部件可由透明的热塑性聚合材料,例如聚甲基丙烯酸甲酯,聚烯烃,例如聚乙烯和聚丙烯等;聚酯、聚氨酯;丙烯酸聚合物,例如聚丙烯酸酯和聚甲基丙烯酸酯;聚碳酸酯等制造,例如它们是采用常规技术模塑成单个单元制造的。
在这样的环境中保存镜片,能抑制细菌在所述镜片上的生长,和抑制细菌增殖产生的不利影响。这种镜片盒的另一个实例,是可在US-6,029,808中找到的镜片盒,特此引入该专利,作为对保存其中公开的隐形眼镜的泡罩型包装的参考。
镜片容器、镜片篮、或顶盖,都可以包含活化银。可以采用与本发明镜片相同的方式,将银加入其余部件的单体混合物中。将所得的混合物装入模具,固化、随后用氧化剂处理。用氧化剂处理模制件的方法,与处理成形的镜片,获得含有活化银的镜片所述的方法相似。在任何或所有的镜片盒部件中,优选活化银的存在量为约0.01至约10重量%(以初始单体混合物为基准计算),更优选约0.05至约3.0%。
为了说明本发明,本申请包括下列实施例。这些实施例并不限制本发明。它们只是推荐实现本发明的方法。对隐形眼镜以及其它专业知识渊博的人,可以找到实现本发明的其它方法。不过,这些方法也被认为是在本发明的范围内。
实施例
在下面的实施例中采用下列缩写:
HEMA 甲基丙烯酸2-羟乙酯
BAGE 用硼酸酯化的甘油
EGDMA 二甲基丙烯酸乙二醇酯
DarocurTM1173 2-羟基-2-甲基-1-苯基-丙-1-酮
MAA 甲基丙烯酸
TRIS 3-甲基丙烯酰氧基丙基三(三甲基甲硅烷氧基)硅烷
DMA N,N-二甲基丙烯酰胺
THF 四氢呋喃
TMI 二甲基β-异丙烯基苄基异氰酸酯
HEMA 甲基丙烯酸2-羟乙酯
TEGDMA 二甲基丙烯酸四甘醇酯
MMA 甲基丙烯酸甲酯
TBACB 间氯苯甲酸四丁铵盐
mPDMS 800-1000MW的一甲基丙烯酰氧基丙基终端的聚二甲基硅氧烷
3M3P 3-甲基-3-戊醇
Norbloc 2-(2′-羟基-5-甲基丙烯酰氧基(methacrylyloxy)乙基苯基)-2H-苯并三唑
CGI1850 1-羟基环己基苯基酮和双(2,6-二甲氧基苯甲酰基)-2,4,4-三甲基苯基氧膦的1∶1(wt)混合物
PVP 聚(N-乙烯基吡咯烷酮)
IPA 异丙醇
GMMA 1-一甲基丙烯酸甘油酯
mPEG350 聚(乙二醇)甲基醚
D3O 3,7-二甲基-3-辛醇
TAA 叔戊醇
蓝色HEMA 在US-5,944,853实施例4中所述的活性蓝4#和HEMA的反应产物
生物学涡旋(Vortex)实验
在下列实施例中指出的地方,采用下列活细菌附着测定。使绿脓假单胞菌培养基ATCC 15442#(ATCC,Rockville,MD)在营养介质中成长过夜。制备细菌接种物,获得最终浓度为1×108个菌落生成单位(cfc)/ml。采用pH7.4±0.2的磷酸盐缓冲盐水(“PBS”)冲洗三个接触镜片。将每个洗过的接触镜片与2ml细菌接种物合并到小玻璃瓶中,小玻璃瓶在37±℃下在振荡器-恒温箱中搅拌2h。用PBS洗涤每个镜片,将镜片放入包含0.05%TweenTM 80的10ml PBS中,在2000rpm下涡旋3min。计数上清液中的活细菌数,将检测附着在三个镜片上的活细菌的结果进行平均。
实施例1
将9.80g HEMA、0.08g EGDMA、0.04g DarocurTM 1173、和纳米尺寸的活化银(99.9+%,Aldrich化学试剂公司(Aldrich Chemicals)生产)的混合物,在9.80g BAGE稀释剂中,用超声波降解1h。将得到的混合物装入模具中,随后在聚苯乙烯中在UV光下暴露30min,使聚合物固化。在固化之后,打开模具,将镜片洗到硼酸盐缓冲盐水中。获得的镜片在5.25v%次氯酸钠水溶液中浸泡10min,然后用0.85v%的生理盐水溶液冲洗5次。采用上述的微生物测定方法测定,附着在镜片上的活绿脓假单胞菌数,与未处理的接触镜片相比,减少99.8%。
实施例2-4
重复实施例1的方法,但加入表1所示的MAA。当与不含银的聚合物组合物相同的镜片对比时,在所有的情况下都使附着的活细菌减少。生物学测定结果示于表1。
表1
实施例1 | 实施例2 | 实施例3 | 实施例4 | |
HEMA,g | 9.80 | 9.80 | 9.80 | 9.80 |
MAA,g | 0.00 | 0.06 | 0.14 | 0.20 |
EGDMA,g | 0.08 | 0.08 | 0.08 | 0.08 |
Darocur 1173,g | 0.04 | 0.04 | 0.04 | 0.04 |
纳米尺寸的Ag | 0.022 | 0.022 | 0.022 | 0.022 |
活细菌的减少率<sup>*</sup> | 99.8% | 99.7% | 99.7% | 99.7% |
实施例5
大分子单体B的制备
在环境温度下,在氮气氛中,向放在干燥箱内的干燥容器中,加入30.0g(0.277mol)双(二甲基氨基)甲基硅烷、13.75ml 1M TBACB(386.0gTBACB在1000ml无水THF中的溶液)溶液、61.39g(0.578mol)对二甲苯、154.28g(1.541mol)甲基丙烯酸甲酯(相对引发剂为1.4equiv)、1892.13(9.352mol)甲基丙烯酸2-(三甲基甲硅烷氧基)乙酯(相对引发剂为8.5equiv)、和4399.78g(61.01mol)THF。将在干燥箱中制备的上述混合物,装入安装有热电偶和完全与氮源连接的冷凝器的干燥圆底三颈烧瓶中。
在一边搅拌一边用氮气吹扫的同时,将反应混合物冷却到15℃。在溶液达到15℃以后,将191.75g(1.100mol)的1-三甲基甲硅烷氧基-1-甲氧基-2-甲基丙烯(1equiv)注入反应容器中。反应放热到约62℃,然后在整个反应剩余物中,计量加入30ml 0.40M 154.4g TBACB在11ml无水THF中的溶液。在反应温度达到30℃后开始计量加入467.56g(2.311mol)甲基丙烯酸2-(三甲基甲硅烷氧基)乙酯(相对引发剂为2.1equiv)、3636.6g(3.463mol)正丁基一甲基丙烯酰氧基丙基聚二甲基硅氧烷(相对引发剂为3.2equiv)、3673.84g(8.689mol)TRIS(相对引发剂为7.9equiv)、和20.0g双(二甲基氨基)甲基硅烷的溶液。
使混合物放热到约38-42℃,然后将混合物冷却到30℃。在这时加入10.0g(0.076mol)双(二甲基氨基)甲基硅烷、154.26g(1.541mol)甲基丙烯酸甲酯(相对引发剂为1.4equiv)、和1892.13g(9.352mol)甲基丙烯酸2-(三甲基甲硅烷氧基)乙酯(相对引发剂为8.5equiv)的溶液,再使混合物放热到约40℃。将反应温度降至约30℃,加入2gal THF降低粘度。加入439.69g水、740.6g甲醇、和8.8g(0.068mol)二氯乙酸的溶液,混合物回流4.5h,解封HEMA上的保护基团。然后除去挥发性物质,加入甲苯有助于除去水,直到蒸气温度达到110℃为止。
将反应烧瓶维持在约110℃,加入443g(2.201mol)TMI和5.7g(0.010mol)二月桂酸二丁基锡的溶液。混合物发生反应,直到用IR检测产生异氰酸酯峰为止。在减压下蒸发甲苯,产生灰白色无水蜡状的活性单体。将大分子单体放入丙酮中,以重量为基准计算,丙酮对大分子单体的比例为约2∶1。在24h后,加水沉淀出大分子单体,过滤大分子单体,采用真空干燥箱在45-60℃下干燥20-30h。
镜片的成形
由下列单体的混合物(所有的量都是按混合物总重量的重量百分数计算的)制备水凝胶:大分子单体B(~18%)、mPDMS(~28%)、TRIS(~14%)、DMA(~26%)、HEMA(~5%)、TEGDMA(~1%)、PVP(~5%);CGI1850(~1%)、冰醋酸(~5%)、和纳米尺寸活化的粉末状银(~0.13%,Aldrich化学试剂公司生产),其余的包括少量的添加剂。聚合作用是在20重量%的二甲基-3-辛醇稀释剂存在下进行的,在固化前用超声波使混合物降解30min。
将约0.10g单体混合物加到US-4,640,489所述类型的8-穴镜片模具的穴中,使接触镜片成形。在50℃(±5)下采用可见光(波长:380-460nm,最大峰在425nm,剂量:约2.5J/cm2)将镜片固化8min。在固化之后,打开模具,使镜片脱模,进入水和乙醇1∶1的混合物中,然后用乙醇沥滤,除去任何残留的单体和稀释剂。最后使镜片在硼酸盐缓冲生理盐水中平衡。虽然在放大下能看到银的颗粒,但用肉眼检查时,镜片看上去是透明的。将获得的镜片在5.25%的次氯酸钠水溶液中浸泡21h,然后用盐水溶液冲洗5次。采用下列方法检验镜片的抗微生物性能:
生物学液体培养基实验
在无氯化钙和氯化镁的情况下,采用Dulbecco’s磷酸盐缓冲盐水洗涤每个镜片,然后将镜片放入1000μl包含108cfu/ml绿脓假单胞菌(ATCC15442)的Mueller Hinton液体培养基中,在37℃下孵化过夜。观察所获溶液的透明度,培养该溶液,计数细菌数,并与不与次氯酸钠反应的类似镜片进行对比。表3中的结果表明,减少的细菌数>99.99%。
表3
实施例5的镜片 | 未与次氯酸钠反应的镜片 | |
溶液透明度 | 透明 | 不透明 |
细菌数,cfu/ml | 3.8×10<sup>4</sup> | 6.2×10<sup>8</sup> |
实施例6-8
由40.67重量%HEMA、1.0%Darocur 1173、1.07%TEGDMA、26.90%GMMA、和30.36%mPEG 350(稀释剂)制备混合物。按表4所示的量,将纳米尺寸活化的粉末状银加到该混合物中。制成镜片,按照实施例1的方法,用次氯酸钠处理。
镜片用高压灭菌器灭菌,采用就在上面所述的微生物测定方法,检测它们的抗微生物性能。结果示于表4。
表4
混合物中的银颗粒 | 细菌数减少的%<sup>*</sup> | |
实施例6 | 0.05重量% | 99.7% |
实施例7 | 0.10重量% | 99.8% |
实施例8 | 0.15重量% | 99.6% |
*与不加银制造的相同组成的镜片对比
实施例9-12
采用实施例5所述的混合物和方法制造镜片,所不同的是不加粉末状银和不与次氯酸钠反应。用无离子水冲洗这些镜片,除去氯离子。将它们在表4所示不同浓度的AgNO3中浸泡30min,吸干除去表面上的水,放入5.0%的抗坏血酸水溶液中。在1h后,用无离子水冲洗镜片,然后如表5所示,分别在5.25%的次氯酸钠或3.0%的过氧化氢水溶液中浸泡10min或60min。用硼酸盐缓冲盐水冲洗镜片,用高压灭菌器杀菌,采用上述的涡旋实验检验抗微生物性能。结果示于表5。
表5
[AgNO<sub>3</sub>] | 氧化剂 | 氧化时间 | 细菌数减少的%<sup>*</sup> | |
实施例9 | 10<sup>-1</sup>M | 5.25%NaOCl | 10min | 99.9% |
实施例10 | 10<sup>-2</sup>M | 5.25%NaOCl | 10min | 99.9% |
实施例11 | 10<sup>-3</sup>M | 5.25%NaOCl | 10min | 99.9% |
实施例12 | 10<sup>-3</sup>M | 3.0%H<sub>2</sub>O<sub>2</sub> | 60min | 99.2% |
*与在不加银和无氧化的条件下制造的镜片对比
实施例13-16
制造实施例5的镜片,但采用0.10%纳米尺寸的银,采用与用硼酸盐缓冲盐水稀释到指定浓度的3.0%过氧化氢溶液在室温下反应表6所示的时间,代替与次氯酸钠反应。采用上述的微生物测定方法检测镜片。结果示于表6。
表6
氧化剂 | 氧化时间 | 细菌数减少的%<sup>*</sup> | |
实施例13 | 1.5%H<sub>2</sub>O<sub>2</sub> | 10min | 96% |
实施例14 | 1.5%H<sub>2</sub>O<sub>2</sub> | 30min | 98% |
实施例15 | 1.5%H<sub>2</sub>O<sub>2</sub> | 60min | 98% |
实施例16 | 0.75%H<sub>2</sub>O<sub>2</sub> | 60min | 99% |
*与组成相同和用H2O2处理过的但不加银制造的镜片对比
实施例17-19
制造实施例5的镜片,但采用0.10%纳米尺寸的银,采用与用硼酸盐缓冲盐水根据需要稀释到指定浓度的50%过氧化氢溶液在室温下反应表7所示的时间,代替与次氯酸钠的反应。采用上述的涡旋实验检测镜片。结果示于表7。
表7
氧化剂 | 氧化时间 | 细菌数减少的%<sup>*</sup> | |
实施例17 | 3.0%H<sub>2</sub>O<sub>2</sub> | 60min | 96% |
实施例18 | 10.0%H<sub>2</sub>O<sub>2</sub> | 60min | 94% |
实施例19 | 50.0%H<sub>2</sub>O<sub>2</sub> | 60min | 91% |
*与组成相同并用H2O2处理过的但不加银制造的镜片对比
实施例20-22
制造实施例5的镜片,但采用与0.05M I2和0.20M KI的水溶液在室温下反应表8所示的时间,代替与次氯酸钠的反应。采用上述的涡旋实验检测镜片。结果示于表8。
表8
氧化剂 | 氧化时间 | 细菌数减少的%<sup>*</sup> | |
实施例20 | 0.05M I<sub>2</sub> | 15min | 80% |
实施例21 | 0.05M I<sub>2</sub> | 60min | 90% |
实施例22 | 0.05M I<sub>2</sub> | 1620min | 92% |
*与etafilcon A镜片对比。当不加银制造时,etafilcon A镜片的抗微生物活性在统计学上与实施例5镜片的活性相同(置信度95%(p=0.09))。
实施例23-25
制造实施例5的镜片,但采用0.20%纳米尺寸的银,采用与用硼酸盐缓冲盐水稀释到指定浓度的3.0%过氧化氢溶液在室温下反应表9所示的时间,代替与次氯酸钠的反应。采用上述的涡旋实验检测镜片。结果示于表9。
表9
氧化剂 | 氧化时间 | 细菌数减少的%<sup>*</sup> | |
实施例23 | 1.5%H<sub>2</sub>O<sub>2</sub> | 10min | 93% |
实施例24 | 1.5%H<sub>2</sub>O<sub>2</sub> | 60min | 90% |
实施例25 | 1.5%H<sub>2</sub>O<sub>2</sub> | 1440min | 92% |
*与不加银制造的与H2O2反应的类似镜片对比
实施例26-35
可将纳米尺寸的银加到表10所列的组合物中。然后可按照实施例5所述的方法制造镜片,用1-2重量%的H2O2氧化。大分子单体A和C是如下制备的:
大分子单体A:
采用大分子单体B的方法,所不同的是采用19.1mol部分的HEMA、5.0mol部分的MAA、2.8mol部分的MMA、7.9mol部分的TRIS、3.3mol部分的mPDMS、和2.0mol部分的TMI。
大分子单体C:
采用大分子单体B的方法,所不同的是采用19.1mol部分的HEMA、7.9mol部分的TRIS、3.3mol部分的mPDMS、和2.0mol部分的TMI。
表10
实施例 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 |
大分子单体 | A | B | C | C | B | B | B | B | B | B |
大分子单体 | 30.00 | 25.00 | 60.00 | 20.00 | 17.98 | 17.98 | 19.98 | 17.98 | 17.98 | 19.98 |
TRIS | 0.00 | 18.00 | 0.00 | 40.00 | 21.00 | 21.00 | 8.00 | 20.00 | 25.00 | 20.00 |
DMA | 27.00 | 28.00 | 36.00 | 36.00 | 25.50 | 25.50 | 26.00 | 22.00 | 9.00 | 23.00 |
mPDMS | 39.00 | 18.00 | 0.00 | 0.00 | 21.00 | 21.00 | 28.50 | 25.50 | 30.00 | 28.50 |
Norbloc | 2.00 | 2.00 | 3.00 | 3.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
CGI1850 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
TEGDMA | 0.00 | 0.00 | 0.00 | 0.00 | 1.50 | 1.50 | 1.50 | 1.50 | 0.50 | 1.50 |
HEMA | 0.00 | 0.00 | 0.00 | 0.00 | 5.00 | 5.00 | 5.00 | 5.00 | 7.00 | 5.00 |
蓝色HEMA | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
PVP | 0.00 | 8.00 | 0.00 | 0.00 | 5.00 | 5.00 | 8.00 | 5.00 | 7.50 | 9.00 |
稀释剂% | 41 | 20 | 20 | 无 | 20 | 50.00 | 37.50 | 20.00 | 40.00 | 50.00 |
稀释剂 | 3M3P | 3M3P | 3M3P | 无价值 | D3O | TAA | 3M3P | TAA | 3M3P | 3M3P |
Claims (16)
1.具有抗微生物性能的光学透明镜片,其中包括0.01至0.3重量%的活化银,并且其中的银在形成镜片之前被加到镜片聚合物中并且随后经由氧化剂处理而活化。
2.权利要求1的镜片,其中镜片是软性接触镜片。
3.权利要求1的镜片,其中镜片是聚硅氧烷水凝胶。
4.权利要求1的镜片,其中含有0.02至0.2重量%的活化银。
5.权利要求1的镜片,其中含有0.05至0.2重量%的活化银。
6.权利要求1的镜片,其中镜片是含有0.02至0.1重量%活化银的聚硅氧烷水凝胶。
7.权利要求6、5或4的镜片,其中镜片是lenefilcon A、aquafilconA、etafilcon A、genfilcon A、balifilcon A、polymacon或lotrafilcon A。
8.权利要求1的光学透明镜片用于制备降低戴镜者对不利微生物反应的光学透明镜片的用途,其中所述光学透明镜片被戴在戴镜者的眼睛内或眼睛上。
9.权利要求8的用途,其中镜片是接触镜片。
10.权利要求8的用途,其中镜片含有0.02至0.2重量%的活化银。
11.权利要求8的用途,其中镜片是含有0.05至0.1重量%活化银的聚硅氧烷水凝胶。
12.生产具有抗微生物性能的光学透明镜片的方法,其中包括0.01至0.3重量%的活化银,该方法包括在形成镜片之前将银加到镜片聚合物中并且随后用氧化剂处理该含银镜片的步骤。
13.权利要求12的方法,其中氧化剂选自过氧化氢、次氯酸钠、过氧酸、溴、氯、铬酸、高锰酸钾和碘。
14.权利要求12的方法,其中氧化剂是次氯酸钠。
15.具有抗微生物性能的镜片盒,其中包括0.01至10重量%的活化银,其中部件镜片容器、镜片篮或顶盖包含活化银,将银加入所述部件的单体混合物中,将所得的混合物装入模具,固化、随后用氧化剂处理,以获得含有活化银的部件。
16.权利要求15的镜片盒,其中盒的至少一个部件含有0.05至3重量%的活化银。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25731700P | 2000-12-21 | 2000-12-21 | |
US60/257,317 | 2000-12-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1630536A CN1630536A (zh) | 2005-06-22 |
CN100363061C true CN100363061C (zh) | 2008-01-23 |
Family
ID=22975788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB01822766XA Expired - Fee Related CN100363061C (zh) | 2000-12-21 | 2001-12-21 | 包含活性银的抗微生物隐形眼镜及其生产方法 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20020197299A1 (zh) |
EP (1) | EP1355681B1 (zh) |
JP (1) | JP2004526187A (zh) |
KR (1) | KR20030063460A (zh) |
CN (1) | CN100363061C (zh) |
BR (1) | BR0116479A (zh) |
CA (1) | CA2432796A1 (zh) |
DE (1) | DE60117863T2 (zh) |
HK (1) | HK1056516A1 (zh) |
TW (1) | TWI229209B (zh) |
WO (1) | WO2002062402A1 (zh) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101021433B1 (ko) * | 2002-08-16 | 2011-03-15 | 존슨 앤드 존슨 비젼 케어, 인코포레이티드 | 콘택트 렌즈 제조용 금형, 렌즈의 제조방법, 렌즈, 및 코팅 렌즈의 제조방법 |
US20040150788A1 (en) | 2002-11-22 | 2004-08-05 | Ann-Margret Andersson | Antimicrobial lenses, processes to prepare them and methods of their use |
US20050008676A1 (en) * | 2002-12-19 | 2005-01-13 | Yongxing Qiu | Medical devices having antimicrobial coatings thereon |
EP2281586A1 (en) * | 2002-12-23 | 2011-02-09 | Johnson and Johnson Vision Care, Inc. | Contact lens packages containing additives |
US8425926B2 (en) * | 2003-07-16 | 2013-04-23 | Yongxing Qiu | Antimicrobial medical devices |
US20050070661A1 (en) * | 2003-09-30 | 2005-03-31 | Frank Molock | Methods of preparing ophthalmic devices |
DE10359338B4 (de) * | 2003-12-17 | 2007-07-19 | Heraeus Kulzer Gmbh | Antimikrobieller Nanosilber-Zusatz für polymerisierbare Dentalmaterialien |
GB0401821D0 (en) * | 2004-01-28 | 2004-03-03 | Qinetiq Nanomaterials Ltd | Method of manufacture of polymer composites |
US20080029408A1 (en) * | 2004-03-17 | 2008-02-07 | Thorkild Andersen | Contact Lens, Container And Insert For Avoiding Infection Of The Eye |
US20060051454A1 (en) * | 2004-08-26 | 2006-03-09 | Ansell Scott F | Molds for producing ophthalmic lenses |
US9297928B2 (en) * | 2004-11-22 | 2016-03-29 | Johnson & Johnson Vision Care, Inc. | Ophthalmic compositions comprising polyether substituted polymers |
US7319133B2 (en) * | 2005-08-09 | 2008-01-15 | Coopervision, Inc. | Contact lens extraction/hydration systems and methods of reprocessing fluids used therein |
EP1913029A1 (en) * | 2005-08-10 | 2008-04-23 | Novartis AG | Silicone hydrogels |
DE102005053295C5 (de) * | 2005-11-08 | 2013-03-07 | Spiegelberg GmbH & Co. KG | Verfahren zur Herstellung eines steril verpackten, metallhaltigen Kunststoffkörpers mit antimikrobiell wirkender Oberfläche |
CA2630854C (en) * | 2005-12-14 | 2016-01-26 | Novartis Ag | Method for preparing silicone hydrogels |
US7960465B2 (en) | 2006-06-30 | 2011-06-14 | Johnson & Johnson Vision Care, Inc. | Antimicrobial lenses, processes to prepare them and methods of their use |
US20080102095A1 (en) | 2006-10-31 | 2008-05-01 | Kent Young | Acidic processes to prepare antimicrobial contact lenses |
ATE530932T1 (de) * | 2007-01-31 | 2011-11-15 | Novartis Ag | Antimikrobielle medizinische vorrichtungen mit silbernanopartikeln |
US20080241225A1 (en) * | 2007-03-31 | 2008-10-02 | Hill Gregory A | Basic processes to prepare antimicrobial contact lenses |
DE102007025452A1 (de) | 2007-05-31 | 2008-12-04 | Ernst-Moritz-Arndt-Universität Greifswald | Verfahren zur Beschichtung von Oberflächen mit Mikro- und Nanopartikeln mit Hilfe von Plasmaverfahren |
US20090092538A1 (en) | 2007-10-08 | 2009-04-09 | Amit Khanolkar | Methods for forming stabilized metal salt particles |
CN102445716A (zh) * | 2010-10-12 | 2012-05-09 | 鸿富锦精密工业(深圳)有限公司 | 镜片、该镜片的制造方法及制造设备 |
AU2018294246A1 (en) | 2017-06-28 | 2020-02-13 | Collidion, Inc. | Compositions, methods and uses for cleaning, disinfecting and/or sterilizing |
MX2020007533A (es) | 2018-01-14 | 2021-01-15 | Collidion Inc | Composiciones, equipos, metodos y usos para la limpieza, desinfeccion, esterilizacion y/o tratamiento. |
CN112695521B (zh) * | 2020-12-25 | 2023-04-28 | 安徽工程大学 | 一种卤胺改性抗菌介孔材料及合成方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5312586A (en) * | 1991-06-21 | 1994-05-17 | Stockel Richard F | Process for sterilizing a contact lens |
US5515117A (en) * | 1993-05-06 | 1996-05-07 | Allergan, Inc. | Antimicrobial lenses and lens care systems |
WO1998018330A1 (en) * | 1996-10-28 | 1998-05-07 | Surfacine Development Company, Llc | Contact-killing non-leaching antimicrobial materials |
WO2000038552A1 (en) * | 1998-12-31 | 2000-07-06 | Healthshield Technologies Llc | Antimicrobial contact lens case |
EP1050314A1 (en) * | 1999-05-07 | 2000-11-08 | Healthshield Technologies L.L.C. | Antimicrobial contact lens |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4476590A (en) * | 1980-03-27 | 1984-10-16 | National Research Development Corporation | Antimicrobial surgical implants |
JPH0476518A (ja) * | 1990-07-19 | 1992-03-11 | Sangi Co Ltd | 抗菌性コンタクトレンズ |
US6267782B1 (en) * | 1997-11-20 | 2001-07-31 | St. Jude Medical, Inc. | Medical article with adhered antimicrobial metal |
-
2001
- 2001-12-20 US US10/027,740 patent/US20020197299A1/en not_active Abandoned
- 2001-12-21 KR KR10-2003-7008463A patent/KR20030063460A/ko not_active Application Discontinuation
- 2001-12-21 DE DE60117863T patent/DE60117863T2/de not_active Expired - Lifetime
- 2001-12-21 EP EP01994478A patent/EP1355681B1/en not_active Expired - Lifetime
- 2001-12-21 CN CNB01822766XA patent/CN100363061C/zh not_active Expired - Fee Related
- 2001-12-21 WO PCT/US2001/050582 patent/WO2002062402A1/en active IP Right Grant
- 2001-12-21 BR BR0116479-1A patent/BR0116479A/pt not_active Application Discontinuation
- 2001-12-21 JP JP2002562407A patent/JP2004526187A/ja active Pending
- 2001-12-21 CA CA002432796A patent/CA2432796A1/en not_active Abandoned
- 2001-12-21 TW TW090131769A patent/TWI229209B/zh not_active IP Right Cessation
-
2003
- 2003-12-09 HK HK03108941A patent/HK1056516A1/xx not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5312586A (en) * | 1991-06-21 | 1994-05-17 | Stockel Richard F | Process for sterilizing a contact lens |
US5515117A (en) * | 1993-05-06 | 1996-05-07 | Allergan, Inc. | Antimicrobial lenses and lens care systems |
WO1998018330A1 (en) * | 1996-10-28 | 1998-05-07 | Surfacine Development Company, Llc | Contact-killing non-leaching antimicrobial materials |
WO2000038552A1 (en) * | 1998-12-31 | 2000-07-06 | Healthshield Technologies Llc | Antimicrobial contact lens case |
EP1050314A1 (en) * | 1999-05-07 | 2000-11-08 | Healthshield Technologies L.L.C. | Antimicrobial contact lens |
Non-Patent Citations (2)
Title |
---|
ANTIMICROBIAL EFFICACY OF A SILVER LAYER ON HYDROGEL LENSES! CITATION. NISSEN S ET AL.DER OPHTHALMOLGE:ZEITSCHRIFT DER DEUTSCHEN OPHTHALMOLOGSCHEN GESELLSCHAFT,Vol.97 No.9. 2000 * |
隐形眼镜保有液细菌污染及紫外线消毒镜片效果的检测. 张丰为,李绥晶,张慧贤.中国消毒学杂志,第15卷第2期. 1998 * |
Also Published As
Publication number | Publication date |
---|---|
CN1630536A (zh) | 2005-06-22 |
WO2002062402A1 (en) | 2002-08-15 |
CA2432796A1 (en) | 2002-08-15 |
US20020197299A1 (en) | 2002-12-26 |
JP2004526187A (ja) | 2004-08-26 |
TWI229209B (en) | 2005-03-11 |
KR20030063460A (ko) | 2003-07-28 |
DE60117863D1 (de) | 2006-05-04 |
DE60117863T2 (de) | 2006-11-16 |
HK1056516A1 (en) | 2004-02-20 |
BR0116479A (pt) | 2004-01-13 |
EP1355681A1 (en) | 2003-10-29 |
EP1355681B1 (en) | 2006-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100363061C (zh) | 包含活性银的抗微生物隐形眼镜及其生产方法 | |
TWI444700B (zh) | 抗菌鏡片,其製法及使用方法 | |
CA2675505C (en) | Antimicrobial medical devices including silver nanoparticles | |
JP3939927B2 (ja) | 眼用レンズ材料およびその製法 | |
CN100522255C (zh) | 抗菌透镜及其制备方法 | |
EP1699497B1 (en) | Antimicrobial contact lenses and methods for their production | |
CN101557841A (zh) | 生物医学装置的表面处理 | |
EP2067797B1 (en) | Silicone polymer, ocular lenses, and contact lens | |
US20040150788A1 (en) | Antimicrobial lenses, processes to prepare them and methods of their use | |
WO2009076029A1 (en) | Method for treating ophthalmic lenses | |
US20090142508A1 (en) | Process for making biomedical devices | |
JP2008505358A (ja) | 眼科用具用包装溶液 | |
WO2009076032A1 (en) | Method for treating ophthalmic lenses | |
US20090142485A1 (en) | Process for Making Biomedical Devices | |
JP2010524016A (ja) | 抗菌コンタクトレンズを作成するための基本的プロセス | |
US8361355B2 (en) | Preparation of antimicrobial contact lenses with reduced haze using swelling agents | |
AU2002246869A1 (en) | Antimicrobial contact lenses containing activated silver and methods for their production | |
WO2024043096A1 (ja) | 被覆医療デバイスおよびその製造方法 | |
CN117716262A (zh) | 用于生产可润湿硅酮水凝胶接触镜片的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080123 Termination date: 20191221 |
|
CF01 | Termination of patent right due to non-payment of annual fee |